I agree that this site is using cookies. You can find further informations here.
X
Place, Amy
39  results:
Search for persons X
?
1

Safety and Efficacy of Apitegromab in Patients With Spinal ..:

Crawford, Thomas O. ; Darras, Basil T. ; Day, John W....
Neurology.  102 (2024)  5 - p. , 2024
Link: https://doi.org/10.1212/..
 
?
2

Advances and limitations for the treatment of spinal muscul..:

Day, John W. ; Howell, Kelly ; Place, Amy...
BMC Pediatrics.  22 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
3

Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis o..:

Crawford, Thomas ; Darras, Basil ; Day, John...
Neurology.  98 (2022)  18_supplement - p. , 2022
Link: https://doi.org/10.1212/..
 
?
4

A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-..:

Place, Amy ; Barrett, Doreen ; Nomikos, George...
Neurology.  96 (2021)  15_supplement - p. , 2021
Link: https://doi.org/10.1212/..
 
?
5

Relationship of pharmacokinetics and pharmacodynamics to ap..:

Crawford, Thomas ; Place, Amy ; Barrett, Doreen...
Journal of the Neurological Sciences.  429 (2021)  - p. 118388 , 2021
Link: https://doi.org/10.1016/..
 
?
6

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacody..:

Barrett, Doreen ; Bilic, Sanela ; Chyung, Yung...
Advances in Therapy.  38 (2021)  6 - p. 3203-3222 , 2021
Link: https://doi.org/10.1007/..
 
?
7

A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-..:

Place, Amy
Neurology.  94 (2020)  15_supplement - p. , 2020
Link: https://doi.org/10.1212/..
 
?
8

Advances and limitations for the treatment of spinal muscul..:

Day, John W ; Howell, Kelly ; Place, Amy...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632131/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
9

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacody..:

Barrett, Doreen ; Bilic, Sanela ; Chyung, Yung...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189951/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
10

Advances and limitations for the treatment of spinal muscul..:

John W. Day ; Kelly Howell ; Amy Place...
https://doi.org/10.1186/s12887-022-03671-x.  , 2022
Link: https://doi.org/10.1186/..
 
?
11

A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacody..:

Adis journals on behalf of (9646730) ; Doreen Barrett (10667312) ; Sanela Bilic (91049)...
https://figshare.com/articles/media/A_Randomized_Phase_1_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_the_Novel_Myostatin_Inhibitor_Apitegromab_SRK-015_A_Potential_Treatment_for_Spinal_Muscular_Atrophy/14447298.  , 2021
Link: https://doi.org/10.6084/..
 
?
12

Heterozygous loss-of-function SMC3 variants are associated ..:

Ansari, Morad ; Faour, Kamli N.W. ; Shimamura, Akiko...
Human Genetics and Genomics Advances.  5 (2024)  2 - p. 100273 , 2024
Link: https://doi.org/10.1016/..
 
?
13

Cardiogenic Shock and the Elderly: Many Questions, Few Answ..:

Place, Scott ; Pisano, Dominic V. ; French, Amy.
Journal of Cardiothoracic and Vascular Anesthesia.  , 2024
Link: https://doi.org/10.1053/..
 
?
14

P408: Perspectives of rare disease experts on sequencing ne..:

Shah, Nidhi ; Gold, Nina ; Adelson, Sophia...
Genetics in Medicine Open.  1 (2023)  1 - p. 100444 , 2023
Link: https://doi.org/10.1016/..
 
?
15

An FDA/CDER perspective on nonclinical testing strategies: ..:

Avila, Amy M. ; Bebenek, Ilona ; Bonzo, Jessica A....
Regulatory Toxicology and Pharmacology.  114 (2020)  - p. 104662 , 2020
Link: https://doi.org/10.1016/..
 
1-15